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The successful treatment of intraabdominal infection requires a combination of anatomical source control and antibiotics. The appropriate duration of antimicrobial
therapy remains unclear.
METHODS

We randomly assigned 518 patients with complicated intraabdominal infection and
adequate source control to receive antibiotics until 2 days after the resolution of
fever, leukocytosis, and ileus, with a maximum of 10 days of therapy (control group),
or to receive a fixed course of antibiotics (experimental group) for 4±1 calendar days.
The primary outcome was a composite of surgical-site infection, recurrent intraabdominal infection, or death within 30 days after the index source-control procedure, according to treatment group. Secondary outcomes included the duration of
therapy and rates of subsequent infections.
RESULTS

Surgical-site infection, recurrent intraabdominal infection, or death occurred in
56 of 257 patients in the experimental group (21.8%), as compared with 58 of
260 patients in the control group (22.3%) (absolute difference, −0.5 percentage
point; 95% confidence interval [CI], −7.0 to 8.0; P = 0.92). The median duration of
antibiotic therapy was 4.0 days (interquartile range, 4.0 to 5.0) in the experimental
group, as compared with 8.0 days (interquartile range, 5.0 to 10.0) in the control
group (absolute difference, −4.0 days; 95% CI, −4.7 to −3.3; P<0.001). No significant between-group differences were found in the individual rates of the components of the primary outcome or in other secondary outcomes.
CONCLUSIONS

In patients with intraabdominal infections who had undergone an adequate sourcecontrol procedure, the outcomes after fixed-duration antibiotic therapy (approximately 4 days) were similar to those after a longer course of antibiotics (approximately 8 days) that extended until after the resolution of physiological
abnormalities. (Funded by the National Institutes of Health; STOP-IT ClinicalTrials
.gov number, NCT00657566.)
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omplicated intraabdominal infection continues to be a common problem
worldwide. Approximately 300,000 cases
of appendicitis occur each year in the United States,1
and at least twice that many cases of non-appendiceal infection require management.2 Morbidity
ranges from 5% among patients evaluated in broad
observational studies2-4 to close to 50% in some
cohorts, such as the elderly or critically ill.5,6 Despite the diversity of specific processes in these
infections, the basic tenets of management are
similar: resuscitate patients who have the systemic
inflammatory response syndrome (SIRS), control
the source of contamination, remove most of the
infected or necrotic material, and administer antimicrobial agents to eradicate residual pathogens.7,8
Antimicrobial therapy for the management of
intraabdominal infections continues to evolve.
Published guidelines include recommendations
for appropriate antimicrobial agents on the basis
of high-quality evidence.7,8 The appropriate duration of therapy, however, remains unclear. Traditionally, practitioners have treated patients until
all evidence of SIRS has resolved, typically for 7 to
14 days. More recently, it has been suggested that
with adequate source control, a shorter course of
3 to 5 days should suffice for cure9 and could decrease the risk of antimicrobial resistance. Currently used guidelines, including those published
jointly by the Surgical Infection Society (SIS) and
the Infectious Diseases Society of America (IDSA),
recommend a treatment course of 4 to 7 days, depending on the clinical response.7,8
Despite these recommendations, observational
studies show that therapy is typically administered
for 10 to 14 days.4,10,11 One reason that shortening
therapy has been difficult is the 20% rate of clinically significant infectious complications after
treatment.3 These subsequent complications, however, are often due to progression of the original
disease or inadequate original source control and
may not be preventable with antimicrobial therapy
alone.
We conducted the randomized Study to Optimize Peritoneal Infection Therapy (STOP-IT) trial
to compare two strategies guiding the duration
of antimicrobial therapy for the management of
complicated intraabdominal infection. We hypothesized that the administration of fixed-duration
antibiotic therapy (4 days) after source control
would lead to equivalent outcomes and a shorter
duration of therapy as compared with the tradin engl j med 372;21

tional strategy of administration of antibiotics
until 2 days after the resolution of the physiological abnormalities related to SIRS.

Me thods
Study Population

Patients were eligible for enrollment in the study
if they were 16 years of age or older; if they presented with a complicated intraabdominal infection with either fever (temperature ≥38.0°C), leukocytosis (≥11,000 peripheral white cells per cubic
millimeter), or gastrointestinal dysfunction due
to peritonitis precluding intake of more than half
their normal diet; and if they had undergone an
intervention to achieve source control.
Source control, defined as procedures that
eliminate infectious foci, control factors that promote ongoing infection, and correct or control
anatomical derangements to restore normal physiological function, is critical to the management
of any infection.12 The adequacy of source control
was confirmed by the local investigator and the
principal investigator of the overall study (see the
full protocol, available with the full text of this
article at NEJM.org).
Study Design and Oversight

In this investigator-initiated, open-label, multicenter trial, we randomly assigned participants in
a 1:1 ratio to receive 4 full days of antimicrobial
therapy after their index source-control procedure
(experimental group) or to receive antimicrobial
therapy until 2 days after the resolution of the
physiological abnormalities related to SIRS (control group). This resolution was defined as a
body temperature of less than 38.0°C for 1 entire
calendar day, normalization of the peripheral
white-cell count to less than 11,000 per cubic
millimeter, and the patient’s ability to consume
more than half of his or her regular diet without
adverse effects.
All the patients or their legal surrogates
provided written informed consent. The specific
choice of antimicrobial agents was not dictated
by the protocol but rather was considered to be
acceptable if it was consistent with published
SIS–IDSA guidelines.7,8
Randomization was performed with the use
of a Web-based data system managed by Merge
Healthcare, an independent contract research organization paid by the sponsor. Each study site
nejm.org
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used a unique randomization sequence. Only 20
patients with appendiceal disease were permitted
in each sequential block of 200 randomly assigned
patients. Patients were enrolled at 23 sites throughout the United States and Canada, and the study
was coordinated through the SIS and managed
by the University of Virginia team. The protocol
was approved by the institutional review board at
each site. All the authors vouch for the accuracy
and completeness of the data, the analyses reported here, and the fidelity of the study to the
protocol.
Duration of Therapy and Adherence
to the Protocol
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coxon signed-rank test, where applicable, in the
intention-to-treat population, which consisted of
all patients who provided consent and underwent
randomization. Kaplan–Meier curves for time to
an event were constructed and compared with
the use of the log-rank test.
Secondary analyses assessed the duration of
antimicrobial therapy for the index infection,
overall exposure to antimicrobial agents, rates of
subsequent extraabdominal infection, and adherence to the protocol. Prespecified subgroups
for analysis included patients with an Acute Physiology and Chronic Health Evaluation (APACHE) II
score of 10 or higher (on a scale of 0 to 71, with
higher scores indicating an increased risk of
death), patients with a health care–associated
infection, patients with an appendiceal source of
index infection and those with a non-appendiceal source of index infection, and patients with
an index infection treated by surgical drainage
and those whose index infection was treated by
percutaneous drainage. Multivariate logistic regression was performed to determine associations with the composite outcome, including key
demographic variables and treatment-group assignments.
According to the original sample-size calculation to define equivalence between the two groups,
we calculated that a sample of 505 patients per
group would be required to give the study 90%
power to detect a 10% difference in complication
rates, assuming a 30% complication rate among
controls and assuming a dropout rate of 10%, at
an alpha level of 0.05. After the first interim
analysis showed nearly identical outcomes in the
two cohorts, a competitive renewal request for
continued support to reach the targeted enrollment
levels was not funded owing largely to a concern
for futility.

After randomization, patients were followed to
assess their clinical course and adherence to the
protocol. In the control group, adherence to the
protocol was defined as the receipt of appropriate antimicrobial agents until 2±1 calendar days
after the first day that the patient had a maximum temperature of less than 38.0°C for 1 whole
calendar day, less than 11,000 peripheral white
cells per cubic millimeter, and the ability to
meet more than half their nutritional needs enterally. A maximum of 10 days of therapy was
allowed for treatment of the initial intraabdominal infection.
In the experimental group, adherence to the
protocol was defined as the receipt of effective
antimicrobial agents for 4±1 calendar days after
the index source-control procedure. Patients were
followed for 30 days after the initial source-control procedure and assessed for infectious complications, use of antimicrobial therapy, and death
from any cause. Patients hospitalized for more
than 30 days were followed to determine hospital length of stay. A resistant pathogen was defined as methicillin-resistant Staphylococcus aureus,
any vancomycin-resistant enterococcus species,
or a gram-negative organism that was resistant
R e sult s
to all members of a major class of antimicrobial
Patient Characteristics and Index Infections
agents.
From August 2008 through August 2013, a total
Statistical Analysis
of 518 patients underwent randomization. One
The primary analysis compared the proportion of patient withdrew consent after randomization.
patients in each group in whom a surgical-site in- Thirty-day follow-up was completed in 99.8% of
fection or recurrent intraabdominal infection de- the patients (Fig. 1).
veloped or in whom death occurred within 30 days
The mean (±SE) age of the patients was
after the index source-control procedure. Analy- 52.2±1.0 years (range, 16 to 88); most of the pases were performed with the use of the chi-square tients were male, and the composition of racial
test with Yates’ correction, Student’s t-test, or Wil- and ethnic groups was similar in the two groups.
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n engl j med 372;21

nejm.org

May 21, 2015

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on June 15, 2015. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

Antimicrobial Ther apy for Intr a abdominal Infection

518 Patients were enrolled and underwent randomization

260 Were assigned to control group
189 Received assigned intervention
71 Did not receive assigned intervention
26 Received more treatment than required
on basis of physiological findings, but
for <10 days total
35 Received treatment for >10 days
6 Had new surgical-site infection
8 Had recurrent intraabdominal infection
1 Had infectious disease owing to extraabdominal infection
20 Had no identifiable reason to receive
>10 days of treatment
10 Received therapy for too few days for
no identifiable reason

258 Were assigned to experimental group
211 Received assigned intervention
47 Did not receive assigned intervention
owing to >5 days of treatment
16 Had ongoing elevated white-cell count
12 Had gastrointestinal dysfunction
6 Had no identifiable reason to receive
>5 days of treatment
2 Had persistent fever
2 Had new surgical-site infection
7 Had recurrent intraabdominal infection
1 Had extraabdominal infection
1 Withdrew consent after receiving antibiotic
therapy

260 Were included in 30-day follow-up

257 Were included in 30-day follow-up

260 Were included in primary intention-to-treat
analysis

257 Were included in primary intention-to-treat
analysis

189 Were included in evaluation of patients who
adhered to study protocol

211 Were included in evaluation of patients who
adhered to study protocol

Figure 1. Enrollment, Randomization, and Treatment.
All enrolled patients had complicated intraabdominal infection and adequate source control. The control group consisted of patients who received antibiotics until 2 days after resolution of fever, leukocytosis, and ileus, with a maximum of 10 days of therapy, and the experimental group received a fixed course of antibiotics for 4±1 calendar days.

The mean APACHE II score for the index infection was 10.1±0.3 (range, 0 to 29), the most common origin of the infection was the colon or rectum, and one third of the infections were treated
with a percutaneous procedure (Table 1). Complete demographic data are provided in Table S1
in the Supplementary Appendix, available at NEJM
.org. There were no differences between the two
study groups, at a significance level of less than
0.05, with respect to any demographic variable.
Adherence to the Protocol

A total of 211 of 258 patients in the experimental
group (81.8%), as compared with 189 of 260 patients in the control group (72.7%), ultimately received antimicrobial therapy for the protocolspecified duration (P = 0.02) (Fig. 1). In the control
group, 10 patients received therapy for too few
n engl j med 372;21

days, including 7 patients who continued to have
an elevated white-cell count and 4 patients who
had ongoing gastrointestinal dysfunction when
therapy was discontinued. Among the other patients who did not receive the assigned therapy,
26 received therapy for less than 10 days (but longer than required according to their physiological
findings) and 35 received therapy for more than
10 days. In some patients in the control group,
the initial course of antimicrobial therapy was
extended owing to a second infection, and they
were considered to be in violation of the protocol; 6 of these patients had a surgical-site infection, 8 had a recurrent intraabdominal infection,
and 1 had an infectious disease owing to extra
abdominal infection.
In the experimental group, all 47 patients who
did not adhere to the protocol received a treatnejm.org
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Table 1. Baseline Demographic and Clinical Characteristics, According to
Study Group.*
Control
Group
(N = 260)

Variable
Age — yr

Experimental
Group
(N = 258)

52.2±1.0

52.2±1.0

145 (55.8)

144 (55.8)

White

208 (80.0)

196 (76.0)

Black

43 (16.5)

51 (19.8)

Asian

5 (1.9)

6 (2.3)

Male sex — no. (%)
Race or ethnic group — no. (%)†

American Indian or Alaskan Native
Hispanic — no. (%)
Other

2 (0.8)

1 (0.4)

20 (7.7)

15 (5.8)

2 (0.8)

4 (1.6)

Characteristics of index infection
APACHE II score‡
Maximum white-cell count — per

mm3

Maximum body temperature — °C

9.9±0.4

10.3±0.4

15,600±0.4

17,100±0.7

37.8±0.1

37.7±0.1

Organ of origin — no. (%)
Colon or rectum

80 (30.8)

97 (37.6)

Appendix

34 (13.1)

39 (15.1)

Small bowel

31 (11.9)

42 (16.3)

Percutaneous drainage

86 (33.1)

86 (33.3)

Resection and anastomosis or closure

69 (26.5)

64 (24.8)

Surgical drainage only

55 (21.2)

54 (20.9)

Resection and proximal diversion

27 (10.4)

37 (14.3)

Simple closure

20 (7.7)

12 (4.7)

3 (1.2)

4 (1.6)

Source-control procedure — no. (%)

Surgical drainage and diversion

*	Plus–minus values are means ±SE. There were no significant differences between the groups (P<0.05).
†	Race and ethnic groups were reported by the patient or surrogate.
‡	Acute Physiology and Chronic Health Evaluation (APACHE) II scores range
from 0 to 71, with higher scores indicating an increased risk of death.

ment course that was longer than the duration
specified in the protocol. Of these patients, 16 had
an ongoing elevated white-cell count, 2 had persistent fever, and 12 continued to have gastrointestinal dysfunction that prevented enteral intake.
A new infection leading to extension of antimicrobial therapy for more than 4 days occurred in
10 patients, including 2 with a surgical-site infection, 7 with a recurrent intraabdominal infection,
and 1 with an extraabdominal infection. Two patients with recurrent intraabdominal infection also
had a persistently elevated white-cell count.
2000
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Primary and Major Secondary Outcomes

The composite primary end point of surgical-site
infection, recurrent intraabdominal infection, or
death occurred in 56 of 257 patients in the experimental group (21.8%), as compared with 58 of 260
patients in the control group (22.3%) (absolute
difference, −0.5 percentage point, 95% confidence
interval [CI], −7.0 to 8.0; P = 0.92) (Table 2). Kaplan–Meier analysis showed no significant between-group difference in the time to the composite primary outcome (Fig. 2).
No significant between-group differences were
seen in the rates of the individual primary-endpoint components of surgical-site infection (absolute difference, −2.2 percentage points; 95% CI,
−2.4 to 7.0; P = 0.43), recurrent intraabdominal infection (absolute difference, 1.8 percentage points;
95% CI, −4.5 to 7.8; P = 0.67), and death (absolute
difference, 0.4 percentage point; 95% CI, −1.7 to
2.7; P = 0.99). Diagnosis of surgical-site infection
and recurrent intraabdominal infection, but not
death, occurred significantly later in the control
group than in the experimental group (Table 2).
Death occurred in 5 of the 518 patients in the
two groups combined (1.0%, 2 patients in the
control group and 3 patients in the experimental
group) at a mean of 18.7±0.4 days after the index
source-control procedure. All the deaths were
judged by the site principal investigator and the
study principal investigator to be related to underlying coexisting diseases (principally cancer and
cardiovascular disease) and not to the initial intraabdominal infection.
The median duration of antimicrobial treatment for the index intraabdominal infection was
4.0 days (interquartile range, 4.0 to 5.0) in the
experimental group, as compared with 8.0 days
(interquartile range, 5.0 to 10.0) in the control
group (absolute difference, −4.0 days; 95% CI,
−4.7 to −3.3; P<0.001). There were significantly
fewer median antimicrobial-free days at 30 days
(including all antimicrobial therapy) in the control group than in the experimental group. No
significant between-group differences were found
with respect to the rates of extraabdominal infection, Clostridium difficile infection, or secondary infections with resistant pathogens (Table 2).
Outcomes in Prespecified Subgroups

The occurrence of the primary composite outcome
was similar in the two study groups in all prespecified subgroups, including patients who were
nejm.org
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Table 2. Primary and Major Secondary Outcomes.*
Control
Group
(N = 260)

Experimental
Group
(N = 257)

P Value

Primary outcome: surgical-site infection, recurrent intraabdominal
infection, or death — no. (%)

58 (22.3)

56 (21.8)

0.92

Surgical-site infection

23 (8.8)

17 (6.6)

0.43

Recurrent intraabdominal infection

36 (13.8)

40 (15.6)

0.67

2 (0.8)

3 (1.2)

0.99

Variable

Death
Time to event — no. of days after index source-control procedure
Diagnosis of surgical-site infection

15.1±0.6

8.8±0.4

<0.001

Diagnosis of recurrent intraabdominal infection

15.1±0.5

10.8±0.4

<0.001

Death

19.0±1.0

18.5±0.5

0.66

9 (3.5)

6 (2.3)

0.62

Any site†

13 (5.0)

23 (8.9)

0.11

Urine

10 (3.8)

13 (5.1)

0.65

Secondary outcome
Surgical-site infection or recurrent intraabdominal infection with
resistant pathogen — no. (%)
Site of extraabdominal infection — no. (%)

Blood

3 (1.2)

5 (1.9)

0.71

Lung

3 (1.2)

3 (1.2)

0.99

Area of skin other than surgical site

1 (0.4)

4 (1.6)

0.36

Vascular catheter

0 (0)

2 (0.8)

0.47

Clostridium difficile infection — no. (%)

3 (1.2)

5 (1.9)

0.71

Extraabdominal infection with resistant pathogen — no. (%)

6 (2.3)

2 (0.8)

0.29

8

4

5–10

4–5

Duration of outcome — days
Antimicrobial therapy for index infection

<0.001

Median
Interquartile range
Antimicrobial-free days at 30 days

<0.001

Median
Interquartile range

21

25

18–25

21–26

7

7

4–11

4–11

Hospitalization after index procedure

0.48

Median
Interquartile range
Hospital-free days at 30 days

0.22

Median
Interquartile range

23

22

18–26

16–26

*	Plus–minus values are means ±SE.
†	Some patients had extraabdominal infections at more than one site.

treated per protocol (33 of 189 patients in the
control group [17.5%] and 37 of 211 patients in
the experimental group [17.5%]; absolute difference, 0.1 percentage point; 95% CI, −7.4 to 7.6;
P = 0.72) (Fig. 3, and Table S2 in the Supplemenn engl j med 372;21

tary Appendix). Differences in the duration of
therapy among patients in all subgroups were
similar to those seen in the intention-to-treat
analysis, with the exception of the subgroup of
patients who were not treated according to the
nejm.org
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1.0

Probability of No Events

0.9

Control group

0.8

Experimental group

0.7
0.6
0.5
0.4
0.3
0.2
P=0.96 by log-rank test

0.1
0.0

0

5

10

15

20

25

30

Days to Composite Outcome
No. at Risk
Control
group
Experimental
group

260

255

243

228

219

210

205

258

253

227

214

208

203

202

Figure 2. Kaplan–Meier Time-to-Event Curves for the Composite Primary
Outcome, According to Treatment Group.
The composite primary outcome was surgical-site infection, recurrent intraabdominal infection, or death.

protocol, for whom the median duration was 11
days in both groups. Results of the logistic-
regression analysis are provided in Table S3 in
the Supplementary Appendix; there was no significant interaction between treatment groups
and the primary composite outcome.

Discussion
In this randomized study involving patients with
complicated intraabdominal infections, a fixed
duration of 4 days of antibiotic treatment resulted in outcomes that were similar to those of
a traditional, longer course that was based on
resolution of physiological abnormalities, and
the shorter course was associated with significantly fewer days of antibiotic exposure. These
data provide support for the concept that after
an adequate source-control procedure, the beneficial effects of systemic antimicrobial therapy
are limited to the first few days after intervention. In addition, it might be argued that the
delay in manifestation of infectious complications in the control group was itself an adverse
outcome, since the time to recognition of these
events and, therefore, the overall time to resolution of all infections was prolonged.
2002
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Traditionally, physicians have administered
antimicrobial therapy in patients who have intraabdominal infections until clinical and laboratory evidence suggests that the infection has
resolved. They reasoned that ongoing sepsis was
indicative of ongoing replication of pathogens.
More recent experimental data, however, suggest
that a prolonged SIRS may be more a reflection
of host immune activity than an indication of
the presence of viable microorganisms.13-15 As
such, efforts have begun to shorten the duration
of antimicrobial therapy in the presence of traditional markers of sepsis. These efforts have
already been successful in other severe infections such as ventilator-associated pneumonia.16
Currently, the average duration of antibiotic
therapy for intraabdominal infection is 10 to 14
days.4,10,11 The results of smaller studies of the
effect of an abbreviated course of antimicrobial
therapy have been published. Schein et al. reported
on an uncontrolled study in which 23 consecutive
patients with diffuse peritonitis were assigned
to receive 3 to 5 days of antibiotics.9 Infections
developed in 22% of these patients; these rates
were similar to those seen in a historical cohort.
Basoli et al., who randomly assigned 90 patients
with mild-to-moderate intraabdominal infection
to either 3 days or 5 or more days of ertapenem
therapy, found no between-group difference in
infectious outcomes.17 Those findings, however,
are not generalizable to the majority of patients
with intraabdominal infection, since half the patients had appendiceal disease and the overall rate
of infectious complications was less than 10%. As
compared with these studies, the STOP-IT trial
had several advantages, including a larger sample
size, randomized design, and enrollment of patients with a broader range of severity of illness.
The rate of infectious complications was more
than 20% in both groups of our study, and most
of these complications were recurrent intraabdominal infections. Given the large difference in
the number of days of treatment in the two study
groups, neither shortening nor lengthening the
duration of antimicrobial therapy appears likely
to affect infectious outcomes. Truly clinically significant improvement in the management of this
disease, therefore, probably awaits more effective
technical or immune response–modifying interventions. However, the observed mortality in our
study was only 1%; this is better than anticipated among patients with a mean APACHE II score
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Subgroup

No. of
Patients

Days of Antibiotic
Therapy

Proportion with Composite Outcome

median
(interquartile range)
Adhered to protocol
Control
Experimental
Did not adhere to protocol
Control
Experimental
APACHE II score ≥10
Control
Experimental
Health care–associated infection
Control
Experimental
Percutaneous drainage
Control
Experimental
Surgical drainage
Control
Experimental
Appendiceal source
Control
Experimental
Non-appendiceal source
Control
Experimental

189
211

7 (5–10)
4 (4–5)

71
47

11 (7–17)
11 (8–19)

120
122

8 (5–10)
4 (4–5)

94
102

8 (5–10)
4 (4–5)

86
86

8 (5–10)
4 (4–5)

174
171

8 (5–10)
4 (4–5)

34
39

8 (5–10)
5 (4–6)

226
218

8 (5–10)
4 (4–5)
0.0

0.1

0.2

0.3

0.4

0.5

Figure 3. Primary Composite Outcome in Key Subgroups.
The median proportions of patients with the composite outcome are shown. I bars indicate the interquartile range.

of 10 and is perhaps related to the reduction in
mortality from many serious infections noted
after the initiation of the Surviving Sepsis Campaign.18
Strengths of the trial include the inclusion of
23 centers and the similarity in outcomes between
the control group and the experimental group in a
wide variety of important, prespecified subgroups.
For example, although rates of complications
differed according to the severity of illness and
the method of source control (percutaneous vs.
surgical drainage), the effect size was similar in
the two study groups. These findings suggest that
the results may well be generalizable across a
wide array of patient populations, care settings,
and interventions, as long as adequate source
control is first achieved.
Several limitations to the interpretation of
these data are worth noting. First, patients without
adequate source control were excluded, and only a
small number of patients with immunosuppression were included; it remains unclear whether
n engl j med 372;21

these populations would benefit from a longer
duration of therapy. Second, the rate of nonadherence to the protocol was moderately high,
including 18% of patients in the experimental
group; this created bias toward the null hypothesis of no difference in therapy, though the fact
that the per-protocol population had similar complication rates between the experimental and
control groups is reassuring. Finally, the original
calculated sample size to assert equivalence between groups was not achieved and proof of
equivalence cannot be claimed, although the 95%
confidence interval for the difference in event rates
was −7.0 to 8.0 and provides encouraging evidence
that the true difference is less than 10%. In other
words, the null hypothesis of equal efficacy cannot be rejected.
In conclusion, outcomes in patients with intraabdominal infections who have undergone a
successful source-control procedure and receive
a fixed, 4-day course of antimicrobial therapy appear to be generally similar to outcomes in panejm.org
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tients in whom systemic antimicrobial agents are
administered until after the resolution of signs
and symptoms of sepsis.
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